Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Johnson & Johnson buy gerihouse

Start price
€113.94
19.04.17 / 50%
Target price
€125.00
26.06.17
Performance (%)
7.94%
End price
€122.24
26.06.17
Summary
This prediction ended on 26.06.17 with a price of €122.24. With a performance of 7.94%, the BUY prediction by gerihouse for Johnson & Johnson closed with a slight gain. gerihouse has 50% into this prediction

Johnson Johnson is a multinational company that focuses on the development, manufacturing, and marketing of a wide range of consumer health products, medical devices, and pharmaceuticals. The company was founded in 1886 and is headquartered in New Jersey, USA. It operates in more than 60 countries and has a diverse portfolio of popular brands including Band-Aid, Tylenol, and Neutrogena. As of 2021, Johnson Johnson has a market capitalization of over $435 billion and is listed on the New York Stock Exchange under the symbol JNJ.

Performance without dividends (%)
Name 1w 1m 1y 3y
Johnson & Johnson -2.434% -2.434% -8.843% 0.103%
iShares Core DAX® -0.992% -3.231% 11.661% 16.545%
iShares Nasdaq 100 -0.225% -3.339% 36.491% 43.334%
iShares Nikkei 225® -0.736% -7.859% 18.597% 4.253%
iShares S&P 500 -0.509% -2.979% 26.341% 40.911%

Comments by gerihouse for this prediction

In the thread Johnson & Johnson diskutieren
Prediction Buy
Perf. (%) 7.94%
Target price 125.000
Change
Ends at 26.06.17

Erwartungen übertroffen


FRANKFURT (Dow Jones) -- Der US-Pharmakonzern Johnson & Johnson hat im ersten Quartal bereinigt mehr verdient als vor Jahresfrist und dabei die Analystenerwartungen übertroffen. Das Unternehmen berichtete am Dienstag über ein Umsatzplus von 1,6 Prozent auf 17,8 Milliarden
US-Dollar. Der Konzern profitierte dabei besonders von einer regen Nachfrage außerhalb des Heimatmarktes.


Der Nettogewinn fiel zwar um 0,8 Prozent auf 4,4 Milliarden  US-Dollar. Das war aber auf ungünstige Sondereffekte zurückzuführen. Bereinigt legte der Gewinn je Aktie um 5,8 Prozent auf 1,83 Dollar zu.
Analysten hatten Johnson & Johnson lediglich 1,77 Dollar zugetraut. Der Pharmakonzern erhöhte die Jahresprognose, um die anstehende Übernahme des Wettbewerbers Actelion zu berücksichtigen. Demnach soll der Umsatz 2017 nun 75,4 bis 76,1 Milliarden Dollar erreichen. Bereinigt soll der Gewinn je Aktie bei 7,00 bis 7,15 Dollar liegen.



Prediction Buy
Perf. (%) 7.94%
Target price 125.000
Change
Ends at 26.06.17

(Vom Mitglied beendet)

Stopped prediction by gerihouse for Johnson & Johnson

buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€167.80
05.08.22
€190.00
05.08.23
-8.34%
06.08.23

buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€142.86
08.07.21
€177.00
08.07.22
22.71%
08.07.22

buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€127.70
09.09.20
€145.00
04.11.21
7.00%
12.02.21

buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€116.60
28.08.19
€145.00
14.04.20
13.72%
14.04.20

buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€116.04
18.07.17
€130.00
08.12.17
4.39%
08.12.17

buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€83.27
21.09.15
€100.00
01.12.15
15.08%
01.12.15

buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€87.67
09.12.14
€99.00
25.03.15
6.68%
25.03.15

buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€80.57
10.10.14
€91.00
17.11.14
6.63%
17.11.14

buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€72.48
22.04.14
€80.00
07.07.14
7.34%
07.07.14

buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€54.70
07.01.13
€62.00
21.02.13
6.12%
21.02.13

buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€52.61
16.10.12
€60.00
06.11.12
5.59%
06.11.12

buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€51.73
14.06.12
€60.00
17.07.12
8.36%
17.07.12